EX-99.1
2
exh99-1_13339.txt
PRESS RELEASE DATED MARCH 7, 2009

                                                                    EXHIBIT 99.1
                                                                    ------------


[LOGO]
ABLE
LABORATORIES, INC.

COMPANY CONTACTS:                                         INVESTOR CONTACT:
Jay Wadekar, Chairman & CEO                               Investor Relations
Nitin V. Kotak, Vice President, Finance and Accounting    Phone (609) 495-2805
Phone (609) 495-2800                                      Email: IR@ablelabs.com

Able Laboratories Reports Financial Results for 2004
Fourth Quarter and Full Year
----------
Net Sales Increase 38% to $31.4 Million for Q4 2004 from $22.8 Million for Q4
2003
----------
Net Sales Increase 33% to $103.2 Million for 2004 from $77.6 Million for 2003
----------
Diluted Earnings per Share Increases 146% to $0.32 for Q4 2004 from $0.13 for Q4
2003
----------
Diluted Earnings per Share Increases 63% to $0.75 for 2004 from $0.46 for 2003
----------

CRANBURY, NJ, MARCH 7, 2005 - ABLE LABORATORIES, INC. (NASDAQ: ABRX) today
announced financial results for the three months and year ended December 31,
2004.

FOURTH QUARTER 2004 FINANCIAL RESULTS

For the fourth quarter of 2004, the Company reported net sales of $31.4 million,
a 38.2% increase from net sales of $22.8 million in the fourth quarter of 2003,
primarily due to the Company's expanded product family. The Company also
reported operating income of $8.5 million for the fourth quarter of 2004, a
135.6% increase compared to operating income of $3.6 million for the fourth
quarter of 2003. These results included an increase in research and development
expenses of $409,000, or 10.9%, compared to the fourth quarter of 2003. Diluted
earnings per share increased to $0.32 for the fourth quarter of 2004 compared to
diluted earnings per share of $0.13 for the fourth quarter of 2003.

Gross profit was $16.5 million for the quarter, an increase of 54.7%, compared
to $10.7 million for the fourth quarter of 2003. The Company's gross profit
margin was 52.5%, compared to 46.9% for the fourth quarter of 2003. Gross margin
increased as a percentage of net sales for the quarter primarily as a result of
selling newly-approved products at higher gross margins.

Dollars invested in research and development expenses increased as a result of
additional research and development conducted to further develop the Company's
product pipeline and costs associated with partnering arrangements. Research and
development expenses were


13.2% of net sales for the fourth quarter of 2004 versus 16.4% of net sales for
the fourth quarter of 2003. The Company currently has six ANDAs pending approval
by the U.S. Food and Drug Administration ("FDA") addressing a total market size
of approximately $500 million. In addition, the Company has 18 projects
currently under development addressing a total market size of approximately $2.6
billion.

Selling, general and administrative expenses increased to $3.8 million for the
fourth quarter of 2004 compared to $3.3 million for the fourth quarter of 2003.
Selling, general and administrative expenses were 12.1% of net sales for the
quarter compared to 14.5% of net sales for the fourth quarter of 2003. The
increase of $508,000 was primarily attributable to increased administrative,
selling and marketing expenses to support the Company's growth.

Operating income for the fourth quarter of 2004 was $8.5 million, or 27.2% of
net sales, versus $3.6 million, or 15.9% of net sales, for the fourth quarter of
2003. The operating income increase is attributable to increased sales and
higher gross profit margins offset by the $917,000 increase in operating
expenses. The effective tax rate for the fourth quarter of 2004 was 25.8%
compared to an effective tax rate of 36.4% for the fourth quarter of 2003. The
decrease in the effective tax rate is primarily due to the recognition of
$864,000 of additional deferred income tax benefits. The recognition of the
additional deferred income tax benefits increased diluted earnings per share by
$0.04. Net income applicable to common stockholders for the quarter was $6.2
million versus $2.4 million for the fourth quarter of 2003. Fully diluted
earnings per share increased 146.2% to $0.32 for the fourth quarter of 2004
versus the $0.13 reported for the fourth quarter of 2003.

FISCAL 2004 FINANCIAL RESULTS

For the year ended December 31, 2004, the Company reported net sales of $103.2
million, a 33.0% increase from net sales of $77.6 million for the year ended
December 31, 2003.

Gross profit was $51.8 million for 2004, an increase of 43.0%, compared to $36.2
million for 2003. The Company's gross profit margin was 50.2% for 2004, compared
to 46.7% for 2003. Gross margin increased as a percentage of net sales primarily
as a result of selling newly-approved products at higher gross margins.

Research and development expenses increased by $4.0 million, or 35.8%, to $15.2
million for 2004 compared to $11.2 million for 2003. Research and development
expenses were 14.8% of net sales for 2004 versus 14.5% of net sales for 2003.
The Company received FDA approval for 16 new products during 2004.

Selling, general and administrative expenses increased to $14.0 million for 2004
compared to $10.7 million for 2003. Selling, general and administrative expenses
were 13.6% of net sales for 2004 compared to 13.8% of net sales for 2003. The
increase of $3.3 million was primarily attributable to increased expenses for
salaries and benefits necessary to support the Company's growth.

Operating income for 2004 was $22.5 million, or 21.8% of net sales, versus $14.3
million, or 18.4% of net sales, for 2003. The operating income increase is
attributable to increased sales and higher gross profit margins partially offset
by the $7.3 million increase in operating expenses. The effective tax rate for
2004 was 33.6% compared to an effective tax rate of 38.9% for 2003. The decrease
in the effective tax rate is primarily due to the recognition of $864,000 of
additional deferred income tax benefits. The recognition of the additional
deferred income tax

                                       2


benefits increased diluted earnings per share by $0.04. Net income applicable to
common stockholders for 2004 was $14.6 million compared to $8.2 million for
2003. Fully diluted earnings per share increased 63.0% to $0.75 for 2004 versus
the $0.46 reported for 2003.

At December 31, 2004, the Company had cash and cash equivalents of $11.7 million
and working capital of $52.0 million compared to cash and cash equivalents of
$20.1 million and working capital of $47.1 million at December 31, 2003. During
2004, we invested approximately $24.3 million in new property and equipment.

FOURTH QUARTER 2004 CORPORATE HIGHLIGHTS

     o    The Company promoted Nitin V. Kotak to Vice President, Finance and
          Accounting. Mr. Kotak has taken over responsibility for the Company's
          financial and accounting management.

     o    The Company entered into a development agreement for a specialty
          prescription generic drug product with Strides, Inc., NJ, a
          wholly-owned subsidiary of Strides Arcolab, Limited, one of India's
          largest manufacturers and exporters of pharmaceutical products.

"We achieved record sales and earnings in the fourth quarter and for the year.
Supported by our 16 ANDA approvals in 2004, we have also seen increased
acceptance of our products by several key customers as a result of the efforts
of our sales management team" commented Jay Wadekar Chairman and CEO of Able
Laboratories, Inc.

"Last year was a transition year for us as we began relocating to the new
facility. We also enhanced our growth prospects by making several key additions
to our management team. We are excited about our R&D plans and partnership
agreements, which we believe, will provide us with opportunities for significant
long term growth."

CONFERENCE CALL INFORMATION

Able Laboratories has scheduled a conference call and web cast regarding this
announcement to be held tomorrow, Tuesday, March 8, 2005, beginning at 10:00
a.m. Eastern Time. To participate in the live call via telephone, please call
(877) 464-5947 or (706) 679-0842 internationally. A telephone replay will be
available for 48 hours following the call by dialing (800) 642-1687 or (706)
645-9291 internationally and entering reservation number 4523818.

Individuals interested in listening to the conference call via the Internet may
do so by visiting our web site www.ablelabs.com. A replay will be available on
the web site for 90 days.

Able Laboratories is a developer and manufacturer of generic pharmaceuticals.
Further information on Able may be found on the Company's web site,
www.ablelabs.com.

EXCEPT FOR HISTORICAL FACTS, THE STATEMENTS IN THIS NEWS RELEASE, AS WELL AS
ORAL STATEMENTS OR OTHER WRITTEN STATEMENTS MADE OR TO BE MADE BY ABLE
LABORATORIES, INC., ARE FORWARD-LOOKING STATEMENTS WITHIN THE MEANING OF THE
PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 AND INVOLVE RISKS AND
UNCERTAINTIES. FOR EXAMPLE, STATEMENTS ABOUT THE COMPANY'S OPERATIONS, ITS
ABILITY TO FORMULATE AND BRING TO MARKET ITS DRUG PRODUCTS UNDER DEVELOPMENT,
ITS ABILITY TO INCREASE SALES AND PROFITS AND MANAGE ITS GROWTH, THE EXPECTED
EFFECTS OF THE COMPANY'S EXPANSION OF ITS PRODUCTION FACILITIES, THE CURRENT OR
EXPECTED MARKET SIZE FOR THE COMPANY'S PRODUCTS, THE ADEQUACY OF THE COMPANY'S
MANUFACTURING CAPACITY, THE AVAILABILITY OF SUFFICIENT CAPITAL, THE SUCCESS OF
CURRENT OR FUTURE PRODUCT OFFERINGS, RESEARCH AND DEVELOPMENT EFFORTS AND THE
COMPANY'S ABILITY TO FILE FOR AND OBTAIN U.S. FOOD AND DRUG ADMINISTRATION
APPROVALS FOR FUTURE PRODUCTS, ARE FORWARD-LOOKING STATEMENTS. FORWARD-LOOKING
STATEMENTS ARE MERELY THE COMPANY'S CURRENT PREDICTIONS OF FUTURE EVENTS, THE
STATEMENTS ARE INHERENTLY UNCERTAIN, AND ACTUAL RESULTS COULD DIFFER MATERIALLY
FROM THE STATEMENTS MADE HEREIN. THERE IS NO ASSURANCE THAT THE COMPANY WILL
CONTINUE TO ACHIEVE THE SALES LEVELS NECESSARY TO MAKE ITS OPERATIONS

                                       3


PROFITABLE OR THAT ITS ANDA FILINGS AND APPROVALS WILL BE COMPLETED AND OBTAINED
AS ANTICIPATED. FOR A DESCRIPTION OF ADDITIONAL RISKS, AND UNCERTAINTIES, PLEASE
REFER TO THE COMPANY'S FILINGS WITH THE SECURITIES AND EXCHANGE COMMISSION,
INCLUDING ITS QUARTERLY REPORT ON FORM 10-Q FOR THE QUARTER ENDED SEPTEMBER 30,
2004 AND ITS ANNUAL REPORT ON FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2003.
THE COMPANY ASSUMES NO OBLIGATION TO UPDATE ITS FORWARD-LOOKING STATEMENTS TO
REFLECT NEW INFORMATION AND DEVELOPMENTS.

                           PLEASE SEE ATTACHED TABLES





































                                       4


                             ABLE LABORATORIES, INC.
                         CONDENSED STATEMENTS OF INCOME
                                   (Unaudited)

Three Months Ended Year Ended ------------------------------ ------------------------------ December 31, December 31, December 31, December 31, 2004 2003 2004 2003 ------------ ------------ ------------ ------------ Sales, net $ 31,435,989 $ 22,752,442 $103,193,652 $ 77,561,115 Cost of sales 14,918,772 12,073,554 51,433,991 41,355,192 ------------ ------------ ------------ ------------ Gross profit 16,517,217 10,678,888 51,759,661 36,205,923 ------------ ------------ ------------ ------------ Operating expenses: Selling, general and administrative 3,817,648 3,309,216 14,001,498 10,696,864 Research and development 4,150,400 3,741,320 15,231,815 11,212,418 ------------ ------------ ------------ ------------ Total operating expenses 7,968,048 7,050,536 29,233,313 21,909,282 ------------ ------------ ------------ ------------ Operating income 8,549,169 3,628,352 22,526,348 14,296,641 ------------ ------------ ------------ ------------ Other income (expense): Interest and financing expense (37,737) (54,378) (188,463) (543,849) Loss on early retirement of debt -- -- (118,440) (241,999) Miscellaneous income (expense), net (190,128) 250,236 (144,612) 388,755 ------------ ------------ ------------ ------------ Other income (expense), net (227,865) 195,858 (451,515) (397,093) ------------ ------------ ------------ ------------ Income before income taxes 8,321,304 3,824,210 22,074,833 13,899,548 Provision for income taxes 2,144,000 1,393,900 7,423,000 5,412,000 ------------ ------------ ------------ ------------ Net income 6,177,304 2,430,310 14,651,833 8,487,548 Dividends on preferred stock 11,712 42,090 89,642 274,559 ------------ ------------ ------------ ------------ Net income applicable to common stockholders $ 6,165,592 $ 2,388,220 $ 14,562,191 $ 8,212,989 ============ ============ ============ ============ Net income per share: Basic $ 0.34 $ 0.14 $ 0.84 $ 0.56 ============ ============ ============ ============ Diluted $ 0.32 $ 0.13 $ 0.75 $ 0.46 ============ ============ ============ ============ Weighted average shares outstanding: Basic 17,983,452 16,536,986 17,401,740 14,709,040 ============ ============ ============ ============ Diluted 19,571,168 19,301,487 19,433,451 18,374,894 ============ ============ ============ ============
5 ABLE LABORATORIES, INC. CONDENSED BALANCE SHEETS (Unaudited) ASSETS
December 31, December 31, 2004 2003 ------------ ------------ Current assets: Cash and cash equivalents $ 11,650,886 $ 20,065,248 Accounts receivable, less allowances of $38,272,886 and $24,007,583 17,878,380 8,626,023 Inventory 18,105,275 16,602,608 Deferred income tax asset 7,500,000 4,760,000 Prepaid expenses and other current assets 1,843,882 1,644,068 ------------ ------------ Total current assets 56,978,423 51,697,947 ------------ ------------ Property and equipment, net 40,228,942 18,953,744 Other assets: Debt financing costs, net of accumulated amortization -- 91,708 Cash deposits with bond trustee -- 525,907 Deferred income tax asset 2,743,000 9,709,000 Goodwill 3,922,655 3,904,094 Deposits and other assets 418,082 481,755 ------------ ------------ Total other assets 7,083,737 14,712,464 ------------ ------------ $104,291,102 $ 85,364,155 ============ ============ LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Notes payable and current portion of long-term debt $ -- $ 239,038 Accounts payable 2,742,823 3,293,168 Accrued expenses 2,268,763 1,114,976 ------------ ------------ Total current liabilities 5,011,586 4,647,182 Long-term debt, less current portion 3,000,000 3,935,000 ------------ ------------ Total liabilities 8,011,586 8,582,182 ------------ ------------ Stockholders' equity: Preferred stock, $.01 par value, 10,000,000 shares authorized, none and 17,025 shares of Series Q outstanding (liquidation value $1,702,500 at December 31, 2003) -- 171 Common stock, $.01 par value, 25,000,000 shares authorized, 18,353,281 and 16,761,216 shares issued and outstanding 183,532 167,611 Additional paid-in capital 120,804,537 116,060,210 Accumulated deficit (24,644,108) (39,295,941) Unearned stock-based compensation (64,445) (150,078) ------------ ------------ Total stockholders' equity 96,279,516 76,781,973 ------------ ------------ $104,291,102 $ 85,364,155 ============ ============
6

The following information was filed by Able Laboratories Inc on Thursday, March 10, 2005 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Able Laboratories Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Able Laboratories Inc.

Continue

Never Miss A New SEC Filing Again


Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.

Continue

We Highlighted This SEC Filing For You


SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.

Continue

Widen Your SEC Filing Reading Experience


Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view

Continue

Uncover Actionable Information Inside SEC Filings


SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q

Continue

Adobe PDF, Microsoft Word and Excel Downloads


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis

Continue

FREE Financial Statements


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator


Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not

Continue

Financial Stability Report


Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity

Continue

Get a Better Picture of a Company's Performance


Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years

Continue

Log in with your credentials

or    

Forgot your details?

Create Account